Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
Peginterferon alfa-2a Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 July 2026
peginterferon alfa-2a: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
Melphalan Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 July 2026
melphalan flufenamide: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
Rurioctocog alfa pegol Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 July 2026
rurioctocog alfa pegol: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
Margetuximab Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 July 2026
margetuximab: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
Lorlatinib Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 July 2026
lorlatinib: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
8 min read
OTUD1 MCP Data Workflow Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
16 July 2026
A visual target evaluation report for OTUD1, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
Latest Hotspot
8 min read
Bivalirudin Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 July 2026
bivalirudin: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
Amikacin Sulfate Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 July 2026
amikacin liposome: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
Acalabrutinib Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 July 2026
acalabrutinib: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
8 min read
OTUB2 MCP Data Workflow Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
16 July 2026
A visual target evaluation report for OTUB2, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
Latest Hotspot
8 min read
Lacosamide Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 July 2026
lacosamide: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
Levofloxacin Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 July 2026
levofloxacin: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.